Carbonic Anhydrase IX targeted radioligand therapeutics for hypoxic solid tumors

Back to all technologies
Download as PDF
NCS: Researchers at Purdue University have discovered radiotherapeutics that target carbonic anhydrase IX (CA IX), a marker of hypoxia. Hypoxia is a common feature of solid tumors and develops because of poorly formed vasculature due to rapid growth of the tumor that outstrips the oxygen supply. Current radiotherapy treatments are non-specific and often toxic with severe side-effects. The Purdue researchers discovered small molecule ligands of CA IX to selectively bind it and deliver the radiotherapeutic.

-Targeted therapy

-Solid tumor treatment
Sep 16, 2022
United States

Sep 24, 2021
United States
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486